A Successful Nodular Basal Cell Carcinoma Defect Closure On The Mid-Cheek Using Modified Mini Cheek Advancement Flap

采用改良型迷你颊部推进皮瓣成功修复面颊中部结节性基底细胞癌缺损

阅读:2

Abstract

Basal cell carcinoma (BCC) is the most common type of malignant skin tumour. This skin cancer is further divided into pigmented, morpheaform, superficial, and nodular BCC (nBCC), as well as fibroepithelioma of Pinkus. Despite its slow growth and very rare metastases, BCC might cause morbidity due to its tendency to relapse as well as its locally invasive nature, especially when located on the face. Wide local excision might be an effective treatment option for BCC and is usually followed by a surgical defect reconstruction procedure. We report a case of 61-year-old woman who presented with a superficially ulcerated, well-defined, hyperpigmented nodule with a rolled edge and frequent episodes of bleeding, as well as suppuration on the right mid-cheek in the past year before the consultation. The lesion was excised and the sample was sent for histopathological examination, revealing tumour mass in a palisading arrangement at the edges, forming solid islands, which is consistent with the diagnosis of nBCC with tumour-free edges. Defect closure with the mini cheek advancement flap (mini-CAF) technique yielded good results after eight months without any recurrence in one year. Skin flap techniques vary widely, among them is the cheek advancement flap technique which might be used for reconstructing defects on the mid-cheek. This flap technique can be modified as mini-CAF by placing a flap incision on the natural creases of the mid-cheek, namely the palpebromalar and nasojugal creases. Mini-CAF offer the advantage as its ability to camouflage the excision line by utilising the natural creases of the face, thus resulting in an aesthetically and functionally favourable result.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。